Get the Stockscreener App
27.04
1.92%
-0.53
After Hours:
27.03
-0.010
-0.04%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $27.04, with a volume of 29.06M.
It is down -1.92% in the last 24 hours and down -2.21% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$27.57
Open:
$27.73
24h Volume:
29.06M
Relative Volume:
0.66
Market Cap:
$153.81B
Revenue:
$62.58B
Net Income/Loss:
$7.79B
P/E Ratio:
19.95
EPS:
1.3551
Net Cash Flow:
$9.08B
1W Performance:
+0.26%
1M Performance:
-2.21%
6M Performance:
+13.80%
1Y Performance:
+8.12%
1-Day Range:
$27.02
$27.77
1-Week Range:
$26.44
$27.80
52-Week Range:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.04 | 156.83B | 62.58B | 7.79B | 9.08B | 1.3551 |
LLY
Lilly Eli Co
|
878.24 | 801.34B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.45 | 576.24B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
209.40 | 373.42B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.63 | 294.04B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
188.42 | 284.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Spotting the Signs of ATTR-CM: Latest Data Reveals Opportunities for More Timely Detection - Pfizer
Vanguard reports 0 Pfizer shares after realignment (NYSE: PFE) - Stock Titan
Why Pfizer Remains A Strong Buy In 2026 (NYSE:PFE) - Seeking Alpha
Jim Cramer Broke Down 5 Stocks Including Pharma Plays for Rising Oil - insidermonkey.com
Is Pfizer’s Late‑Stage Lyme Vaccine Progress Reshaping the Investment Case for PFE? - simplywall.st
Local Anesthesia Drugs Market Is Going to Boom Rapidly | Septodont, Pfizer Inc., Pacira BioSciences, Inc. - openPR.com
Pfizer Inc (PFE): Our Calculation of Intrinsic Value - The Acquirer's Multiple
Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data - insidermonkey.com
Why the Market Dipped But Pfizer (PFE) Gained Today - Yahoo! Finance Canada
Pfizer Options Spot-On: On March 26th, 100.37K Contracts Were Traded, With 2.39 Million Open Interest - Moomoo
Could Buying Eli Lilly Today Set You Up for Life? - The Motley Fool
Federal Circuit schedules oral argument in Enanta’s patent case against Pfizer - Investing.com
Income Investors Face a Hard Truth About Pfizer’s Payout Safety - Yahoo Finance
Pfizer Lyme Vaccine Readout Adds New Angle To Valuation Debate - simplywall.st
After Five Years of Sluggish Performance, Pfizer Finds Renewed Hope in High Dividends and Clinical Data - NAI500
Lyme disease vaccine 70 percent effective: Pfizer - MSN
Pfizer Inc. stock steady as Guggenheim hikes target to $36 amid Lyme vaccine Phase 3 success - ad-hoc-news.de
Is Pfizer Stock a Buy After This Win? - The Globe and Mail
Pfizer (NYSE:PFE) Shares Up 1.2% After Analyst Upgrade - MarketBeat
Pfizer Options Spot-On: On March 25th, 76,121 Contracts Were Traded, With 2.36 Million Open Interest - Moomoo
Pfizer Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Pfizer/Metsera wins Matter of the Year at GCR Awards - globalcompetitionreview.com
Pfizer Inc. (PFE) Announces Positive Topline Results From Phase 3 TALAPRO-3 Study of TALZENNA® - Yahoo Finance
A Lyme Disease Vaccine May Be on the Way - inc.com
Pfizer: Undervalued High-Yield Giant With A Pipeline Built For The Next Decade (NYSE:PFE) - Seeking Alpha
Pfizer's trispecific antibody shows promise against eczema - BioXconomy
Pensionfund Sabic Makes New $1.86 Million Investment in Pfizer Inc. $PFE - MarketBeat
Pfizer's Comirnaty Vaccine Variant-Adapted for 2025/2026 Season Gains Global Launch Momentum Amid Ob - AD HOC NEWS
Oil Volatility Shakes Markets – Life Sciences Stocks Back in Focus: Bayer, Vidac Pharma, Valneva, Novo Nordisk, and Pfizer - news.financial
Pfizer: Time To Buy The Turnaround (NYSE:PFE) - Seeking Alpha
Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts - BioSpace
Pfizer Inc. stock steady amid Guggenheim target hike to $36 and fresh Lyme vaccine data as analysts - AD HOC NEWS
Doctors say Pfizer's Lyme disease vaccine trial results 'encouraging' after more than 70% efficacy shown - abcnews.com
Doctors say Pfizer’s Lyme disease vaccine trial results ‘encouraging’ after more than 70% efficacy shown - Rural Radio Network
Pfizer Options Spot-On: On March 24th, 87,620 Contracts Were Traded, With 2.32 Million Open Interest - Moomoo
Pfizer Inc. stock navigates mini-tender warning and Guggenheim target hike amid pipeline optimism - AD HOC NEWS
Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial - Yahoo Finance
Pfizer Reports 73% Lyme Vaccine Efficacy as Trial Results Complicate Outlook - TradingView
Press Release: Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call With Analysts - Moomoo
Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Pfizer Inc. stock faces mini-tender warning amid Guggenheim target hike and valuation debate - AD HOC NEWS
Pfizer (NYSE:PFE) Price Target Raised to $36.00 - MarketBeat
Guggenheim Raises Pfizer (PFE) Price Target to $36 with a Buy Ra - gurufocus.com
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Guggenheim raises Pfizer stock price target on drug trial outlook - Investing.com
Pfizer Inc. $PFE Shares Acquired by SG Americas Securities LLC - MarketBeat
Park Place Capital Corp Trims Position in Pfizer Inc. $PFE - MarketBeat
PFIZER INC : Jefferies keeps its Buy rating - marketscreener.com
Guggenheim Adjusts Pfizer's PT to $36 From $35, Keeps Buy Rating - marketscreener.com
E. Ohman J or Asset Management AB Purchases Shares of 140,617 Pfizer Inc. $PFE - MarketBeat
Anti Venom Market Set for Significant Growth| Pfizer, Inc. and Merck & Co. - openPR.com
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
2.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):